Home › NDC Lookup › RxCUI directory › RxCUI 2693899

15 ML atezolizumab-tqjs 125 MG/ML / hyaluronidase-tqjs 2000 UNT/ML Injection [Tecentriq Hy... — RxCUI 2693899

RxNorm drug concept · Semantic branded drug
RxCUI 2693899 Semantic branded drug · SBD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2693899
Official name15 ML atezolizumab-tqjs 125 MG/ML / hyaluronidase-tqjs 2000 UNT/ML Injection [Tecentriq Hybreza]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known asTecentriq Hybreza (atezolizumab-hyaluronidase-tqjs 1875 MG / 30,000 UNT) per 15 ML Injection; Tecentriq Hybreza 1875 MG / 30,000 UNT in 15 ML Injection
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)17 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Atezolizumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Tecentriq treats several types of cancer — non-small cell lung cancer (both after surgery and when it has spread), extensive-stage small cell lung cancer, liver cancer (hepatocellu...
  • What cancers is Tecentriq actually approved to treat?
  • No — Tecentriq is given as an IV infusion at a clinic or infusion center, not as a pill you take at home. Your first infusion takes about 60 minutes. If you handle that well, later...
  • How is Tecentriq given — do I take a pill at home?
📖 Read our full Atezolizumab Injection guide →

🕸️ Concept Web — How 15 ML atezolizumab-tqjs 125 MG/ML / hyaluronidas... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 15 ML atezolizumab-tqjs 125 MG/ML / hyaluronidase-tqjs 2000 UNT/ML Injection [Tecentriq Hybreza] RxCUI 2693899

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Atezolizumab 1792776
    • Hyaluronidase 5464
    • Atezolizumab / hyaluronidase 2693887
    • Atezolizumab-tqjs 2693883
    • Hyaluronidase-tqjs 2693885
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tecentriq Hybreza 2693894
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Atezolizumab / hyaluronidase Injection 2693889
    • Atezolizumab-tqjs / hyaluronidase-tqjs Injection 2693891
    • Atezolizumab / hyaluronidase Injectable Product 2693888
    • Atezolizumab-tqjs / hyaluronidase-tqjs Injectable Product 2693890
    • Atezolizumab / hyaluronidase Injection [Tecentriq Hybreza] 2693897
    • Atezolizumab-tqjs / hyaluronidase-tqjs Injection [Tecentriq Hybreza] 2693898
    • Tecentriq Hybreza Injectable Product 2693896
    • Injection 1649574
    • +1 more in this family
  4. Clinical & branded drugs 4

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 18 of 19 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 15 ML atezolizumab-tqjs 125 MG/ML / hyaluronidase-tqjs 2000 UNT/ML Injection SCD · 2693892
  • Atezolizumab-tqjs 125 MG/ML SCDC · 2693884
  • Hyaluronidase-tqjs 2000 UNT/ML SCDC · 2693886
  • Atezolizumab / hyaluronidase Injection SCDF · 2693889
  • Atezolizumab-tqjs / hyaluronidase-tqjs Injection SCDFP · 2693891
  • Atezolizumab / hyaluronidase Injectable Product SCDG · 2693888
  • Atezolizumab-tqjs / hyaluronidase-tqjs Injectable Product SCDGP · 2693890

Brand-Name Concepts

  • Atezolizumab-tqjs 125 MG/ML / hyaluronidase-tqjs 2000 UNT/ML [Tecentriq Hybreza] SBDC · 2693895
  • Atezolizumab / hyaluronidase Injection [Tecentriq Hybreza] SBDF · 2693897
  • Atezolizumab-tqjs / hyaluronidase-tqjs Injection [Tecentriq Hybreza] SBDFP · 2693898
  • Tecentriq Hybreza Injectable Product SBDG · 2693896
  • Tecentriq Hybreza BN · 2693894

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2693899 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50242-0933-01 1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-01) / 15 mL in 1 VI... Tecentriq Hybreza Genentech, Inc. 2024-09-12
50242-0933-86 1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-86) / 15 mL in 1 VI... Tecentriq Hybreza Genentech, Inc. 2024-09-12
Observed labelers: Genentech, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🧾 Billing Codes (HCPCS)

Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
CodeDescriptorMapped packagesSources
J9024 Inj atezolizumb 5mg hya-tqjs 1 CMS
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.